Top Gainers Technical Data -- Research on BioScrip, E-House China Holdings, MagneGas, and Idera Pharma

LONDON, April 9, 2014 /PRNewswire/ --

On Tuesday, April 08, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrials and Telecommunication Services sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), E-House China Holdings Ltd (NYSE: EJ), MagneGas Corp. (NASDAQ: MNGA) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on BIOS, EJ, MNGA and IDRA can be downloaded upon signing up at:

http://www.investor-edge.com/954-register

BioScrip Inc.'s stock edged 5.81% higher, finishing Tuesday's session at $7.19. The stock fluctuated between $7.02 and $7.44 during the session with a trading volume of 3.47 million shares as compared with its three months average volume of 1.76 million shares. BioScrip Inc.'s shares have declined 2.31% in the previous three months and 2.84% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 0.80% during the trading session, while the same has charted up 1.47% in the previous three months. BioScrip Inc.'s stock is trading below its 50-day and 200-day moving averages of $7.68 and $9.68, respectively. Furthermore, the company's stock has a Relative Strength Index (RSI) of 40.06. Sign up today to read free research on BIOS at:

http://www.investor-edge.com/954-BIOS-09Apr2014.pdf

Shares in E-House China Holdings Ltd finished Tuesday's session at $11.48, up 9.33%. A total of 3.09 million shares were traded which is above its three months average volume of 2.60 million shares. The stock vacillated between $10.19 and $11.50 during the session. Shares in E-House China Holdings Ltd have lost 24.62% in the last one month and 23.87% on YTD basis. The S&P 500 Financials Sector Index mapped a gain of 0.13% during the trading session, while the same has fallen by 2.05% in the last one month. Additionally, the company's stock has an RSI of 30.60 and is trading above its 200-day moving average of $9.95. Sign up today to read free research on EJ at:

http://www.investor-edge.com/954-EJ-09Apr2014.pdf

On Tuesday, shares in MagneGas Corp. ended the session at $1.55, up 8.39%, with a trading volume of 2.51 million shares as compared with its three months average volume of 2.71 million shares. During the session, the stock traded between $1.42 and $1.60. MagneGas Corp.'s shares have rallied 104.18% in the last one month, 53.47% in the previous three months, and 252.27% on YTD basis. The S&P 500 Industrials Sector Index mapped a loss of 0.01% during the trading session and has declined 1.94% in the last one month. Further, the company's stock has an RSI of 52.71 and is trading above its 50-day and 200-day moving averages of $1.06 and $0.79, respectively. Sign up today to read free research on MNGA at:

http://www.investor-edge.com/954-MNGA-09Apr2014.pdf

Shares in Idera Pharmaceuticals Inc. closed Tuesday's session at $3.77, up 4.14%, after oscillating between $3.65 and $3.85. A total of 2.21 million shares were traded, which is below its three months average volume of 3.68 million shares. Shares in Idera Pharmaceuticals Inc. have declined 34.78% in the last one month and 18.57% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 0.80% during the trading session and 4.04% in the last one month. Moreover, the company's stock has an RSI of 34.32 and is trading above its 200-day moving average of $2.91. On April 7, 2014, the company presented new preclinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400. These data add to the growing body of research which supports the Company's efforts to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma. Sign up today to read free research on IDRA at:

http://www.investor-edge.com/954-IDRA-09Apr2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Investor-Edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED